RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orphazyme A/S - Stock

Orphazyme A/S Debt 2024

Orphazyme A/S Debt

-11.27 DKK

Ticker

ORPHA.CO

ISIN

DK0060910917

WKN

A2H7EV

In 2024, Orphazyme A/S's total debt was -11.27 DKK, a -73.46% change from the -42.46 DKK total debt recorded in the previous year.

Orphazyme A/S Aktienanalyse

What does Orphazyme A/S do?

Orphazyme A/S is a Danish biopharmaceutical company specializing in the development of therapies for rare neurodegenerative diseases. They focus on researching amyloids, insoluble protein complexes found in various neurodegenerative diseases. Their business model involves developing and marketing therapeutic treatments for these rare neurodegenerative diseases. They specialize in four disease areas: Niemann-Pick disease type C (NPC), Gaucher disease, sporadic inclusion body myositis (sIBM), and amyotrophic lateral sclerosis (ALS). They concentrate on developing drugs that control lysosomal function and the breakdown of biocatalysts. Their advanced product, Arimoclomol, is currently being tested in a Phase 3 trial for the treatment of NPC disease. Orphazyme has collaborations with other companies and research institutions to advance their research and development efforts. These include a partnership with Sobi for the exclusive rights to market Arimoclomol in Europe and a collaboration with QIAGEN to develop biomarkers for diagnosing NPC disease. Overall, Orphazyme is a promising company focused on providing much-needed solutions for rare neurodegenerative diseases through their pipeline of therapies. They are well-positioned to become a leading player in the biopharmaceutical industry in the future. Orphazyme A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Orphazyme A/S's Debt Structure

Orphazyme A/S's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Orphazyme A/S's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Orphazyme A/S’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Orphazyme A/S’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Orphazyme A/S Stock

What is the debt of Orphazyme A/S this year?

Orphazyme A/S has a debt level of -11.27 DKK this year.

What was the debt of Orphazyme A/S compared to the previous year?

The debt of Orphazyme A/S has increased by -73.46% compared to the previous year dropped.

What are the consequences of high debt for investors in Orphazyme A/S?

High debt can pose a risk for investors of Orphazyme A/S, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Orphazyme A/S?

Low debt means that Orphazyme A/S has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Orphazyme A/S affect the company?

An increase in debt of Orphazyme A/S can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Orphazyme A/S affect the company?

A reduction in debt of Orphazyme A/S can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Orphazyme A/S?

Some factors that can influence the debt of Orphazyme A/S include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Orphazyme A/S so important for investors?

The debts of Orphazyme A/S are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Orphazyme A/S take to change the debt?

To change the debt, Orphazyme A/S can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Orphazyme A/S pay?

Over the past 12 months, Orphazyme A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orphazyme A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Orphazyme A/S?

The current dividend yield of Orphazyme A/S is .

When does Orphazyme A/S pay dividends?

Orphazyme A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orphazyme A/S?

Orphazyme A/S paid dividends every year for the past 0 years.

What is the dividend of Orphazyme A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orphazyme A/S located?

Orphazyme A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orphazyme A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orphazyme A/S from 6/27/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Orphazyme A/S pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Orphazyme A/S in the year 2023?

In the year 2023, Orphazyme A/S distributed 0 DKK as dividends.

In which currency does Orphazyme A/S pay out the dividend?

The dividends of Orphazyme A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orphazyme A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orphazyme A/S

Our stock analysis for Orphazyme A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orphazyme A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.